key: cord-0704831-8msyd8pb
authors: Ganmaa, Davaasambuu; Wang, Rui; Willett, Walter C.; Manson, JoAnn E.
title: Response to the letter to the editor: “The link between Vitamin D and COVID-19”
date: 2021-05-29
journal: Contemp Clin Trials
DOI: 10.1016/j.cct.2021.106418
sha: 1da37f6c49a93269843ee4ffd1a053498219e49d
doc_id: 704831
cord_uid: 8msyd8pb

nan

Response to the letter to the editor: "The link between Vitamin D and COVID-19" Camposa et al. [1] propose that we consider using larger doses of vitamin D3 supplementation in our randomized trial [2] . In the VItamin D and COVID-19 (VIVID) trial, we are testing vitamin D 3 supplementation for prevention of moderate or severe COVID-19 illness requiring healthcare visits, as well as its role for post-exposure prophylaxis among those with a household member with the infection.

To clarify a few points about our design:

• We propose administering 10,000 IU per day for two days followed by 3200 IU per day for the remaining 4 weeks, in order to quickly raise levels among those whose levels are low to a replete level, without incurring the adverse events that can occur with high-dose bolus dosing) [3, 4] . These doses are high enough to achieve and maintain serum 25(OH)D levels of at least 30 ng/ml (75 nmol/l) in most participants [5] , but are below the upper intake limit set by the Institute of Medicine of 4000 IU/day for adults) [6] . We expect these doses will also help to attenuate the cytokine-mediated inflammatory response seen in more severe COVID-19 [2] .

• In choosing the dose, we considered evidence from prior RCTs testing vitamin D in acute respiratory infections (ARIs). The few trials that used a large bolus dose did not show evidence of benefit. Among residents of assisted living facilities in London, giving 96,000 or 120,000 IU of vitamin D for 2 months followed by 400 /IU day did not influence risk of ARI in older adults and was associated with increased duration of upper respiratory tract infections [7] . Bolus dosing of vitamin D also did not influence the duration or severity of upper respiratory infections [8] or outcomes following community--acquired pneumonia [9] . Of note, our meta-analysis of vitamin D trials revealed no benefit of bolus dosing in preventing ARIs, but did show a protective effect of daily or weekly regimens. [10] . It has been postulated that high vitamin D concentrations after bolus dosing may dysregulate enzymes responsible for synthesis and degradation of the active vitamin D metabolite [11] and attenuate its ability to support protective immune responses.

• We also believe that our vitamin D dosing is appropriate for the question of post-exposure prophylaxis. • We are measuring 25(OH)D levels at baseline and at 4 weeks in most participants, although a subset will have measurements at 1 or 2 weeks to assess the time course of the response to supplementation. The blood will be sampled by fingerprick, using a microsampling device. We are not specifically targeting a vitamin D deficient population because of ethical concerns about randomizing half to placebo among a deficient group. In fact, we have advocated that during the COVID-19 pandemic, it is particularly important to avoid vitamin D deficiency [12] .

• Finally, an additional follow-up survey will be done at 8 weeks to assess persistence of symptoms; this will allow us to evaluate whether vitamin D supplementation hastens recovery from COVID-19 and reduces the risk of the post-acute sequelae of COVID-19 syndrome.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The link between vitamin D and COVID 19

The vitamin D for COVID-19 (VIVID) trial: a pragmatic cluster-randomized design

Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial

Effect of high-dose vitamin D supplementation on volumetric bone density and bone strength: a randomized clinical trial

Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol

Dietary Reference Intakes for Calcium and Vitamin D

Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu)

Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial

Effect of adjunctive single high-dose vitamin D3 on outcome of community-acquired pneumonia in hospitalised adults: The VIDCAPS randomised controlled trial

Contents lists available at ScienceDirect Contemporary Clinical Trials journal homepage

Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data

How to optimize vitamin D supplementation to prevent cancer, based on cellular adaptation and hydroxylase enzymology

Eliminating vitamin D deficiency during the COVID-19 pandemic: A call to action